# Hypervision Surgical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hypervision-surgical

- Industry: Healthcare IT
- Headquarters: London, UK
- Website: www.hypervisionsurgical.com
- Total disclosed funding: $31M
- Latest round: Series A (Apr 29, 2026)
- Investors on record: 10

## About

Based in London, UK, and co-founded by Michael Ebner (CEO), Tom Vercauteren (CSO), Sébastien Ourselin (Board Director), and Jonathan Shapey (clinical need) in 2020 as a spin-out company of King's College London, Hypervision Surgical Ltd operates as a Healthcare IT company. In April 2026, Hypervision Surgical Ltd raised GBP 17 million in series A funding led by new investor Heal Capital with participation from other new investors Angelini Ventures, IP Group, and Daycrest. Returning investors HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures also participated in the round.

The company provides advanced computer-assisted tissue analysis technology, using AI (artificial intelligence) powered hyperspectral imaging. The company offers real-time, wide-field tissue information that enhances surgical precision and patient safety. Hypervision Surgical's technology utilizes non-contact, non-invasive optical imaging that does not require any contrast agents. They employ AI algorithms to provide quantitative tissue analysis, including perfusion assessment and tissue differentiation in real-time. Hyperspectral imaging splits light into multiple spectral bands beyond what the human eye can perceive, enabling objective tissue characterization. This tissue information is crucial for guiding surgical procedures effectively.

Hypervision generates revenue through sales of its hyperspectral imaging hardware systems, including the HYPERSNAP platform, deployed in surgical environments. Additional revenue is derived from software subscriptions and licensing of its AI-powered analytics platform, providing real-time intraoperative insights. The company may also generate income through service agreements, clinical integration partnerships, and collaborations with medical device manufacturers and healthcare providers seeking advanced surgical imaging and data-driven decision support solutions.

Hypervision plans to scale its Hyperspectral Intelligence platform across clinical environments by increasing adoption in hospitals and integrating its technology into laparoscopic, robotic, and minimally invasive surgical systems. The company will continue advancing its next-generation spectral sensing technology in collaboration with imec, while expanding its cloud-enabled analytics capabilities. Growth is expected through broader commercial deployment, regulatory expansion, and positioning the platform as a data-driven standard for real-time intraoperative decision-making.

## Funding rounds

- Series A, Apr 29, 2026, $23M — Redalpine, Macmillan Cancer Support, LifeX Ventures, Heal Capital, HERAN Partners, Angelini Ventures, ZEISS Ventures, IP Group, Sages Ingenuity, Daycrest
- Seed, May 5, 2023, $8.2M — Redalpine, LifeX Ventures, HERAN Partners, ZEISS Ventures

## Investors

- Redalpine (https://capitalatlas.ai/funds/redalpine) — Seed, Series A
- LifeX Ventures (https://capitalatlas.ai/funds/lifex-ventures) — Seed, Series A
- HERAN Partners (https://capitalatlas.ai/funds/heran-partners) — Seed, Series A
- ZEISS Ventures (https://capitalatlas.ai/funds/zeiss-ventures) — Seed, Series A
- Macmillan Cancer Support — Series A
- Heal Capital (https://capitalatlas.ai/funds/heal-capital) — Series A
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series A
- IP Group — Series A
- Sages Ingenuity (https://capitalatlas.ai/funds/sages-ingenuity) — Series A
- Daycrest — Series A